BeyondSpring (BYSI) Assets Average (2017 - 2026)
BeyondSpring (BYSI) posted Assets Average of $22.2 million for Q1 2026, down 19.99% sequentially from $27.7 million in Q4 2025, and down 37.92% YoY from $35.7 million in Q1 2025.
BeyondSpring (BYSI) Assets Average (2017 - 2026) Analysis & Trends
BeyondSpring has reported Assets Average for 9 years, with the latest figure at $22.2 million in Q1 2026.
- Quarterly Assets Average fell 37.92% year-over-year to $22.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $22.2 million (down 37.92% YoY) and the FY2025 annual result came in at $30.1 million, up 1.9% from the prior year.
- Assets Average slipped to $22.2 million in Q1 2026 per BYSI's latest filing, from $27.7 million in the prior quarter.
- Over five years, Assets Average peaked at $72.7 million in Q2 2022 and troughed at $22.2 million in Q1 2026.
- A 4-year average of $38.4 million and a median of $34.1 million in 2025 frame the typical range for Assets Average.
- The sharpest annual moves came in 2022 and 2023: Assets Average decreased 19.05% in 2022, then plunged 47.55% in 2023.
- Over 4 years, Assets Average stood at $55.0 million in 2022, then plunged by 47.55% to $28.8 million in 2023, then declined by 3.93% to $27.7 million in 2025, then retreated by 19.99% to $22.2 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $22.2 million, $27.7 million, and $30.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | BeyondSpring | 29.85 Mn | 29.85 Mn | - | 16.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 16.51 Mn |
| Mar 31, 2026 | 22.17 Mn |
| Dec 31, 2025 | 27.71 Mn |
| Sep 30, 2025 | 30.26 Mn |
| Jun 30, 2025 | 34.07 Mn |
| Mar 31, 2025 | 35.71 Mn |
| Dec 31, 2023 | 28.84 Mn |
| Jun 30, 2023 | 39.55 Mn |
| Dec 31, 2022 | 54.99 Mn |
| Jun 30, 2022 | 72.71 Mn |
| Dec 31, 2021 | 90.01 Mn |
| Sep 30, 2021 | 90.45 Mn |
| Jun 30, 2021 | 89.81 Mn |
| Mar 31, 2021 | 107.07 Mn |
| Dec 31, 2020 | 78.22 Mn |
| Sep 30, 2020 | 43.06 Mn |
| Jun 30, 2020 | 40.11 Mn |
| Mar 31, 2020 | 39.03 Mn |
| Dec 31, 2019 | 39.35 Mn |
| Sep 30, 2019 | 20.08 Mn |